Last reviewed · How we verify
ATB-1013
ATB-1013 is an autotaxin inhibitor that reduces lysophosphatidic acid (LPA) production to modulate immune and fibrotic responses.
ATB-1013 is an autotaxin inhibitor that reduces lysophosphatidic acid (LPA) production to modulate immune and fibrotic responses. Used for Systemic sclerosis (scleroderma).
At a glance
| Generic name | ATB-1013 |
|---|---|
| Sponsor | Autotelicbio |
| Drug class | Autotaxin inhibitor |
| Target | Autotaxin (ATX) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Fibrosis |
| Phase | Phase 3 |
Mechanism of action
Autotaxin is an enzyme that generates lysophosphatidic acid, a lipid mediator involved in inflammation, fibrosis, and immune cell activation. By inhibiting autotaxin, ATB-1013 decreases LPA levels, which may reduce pathological immune responses and fibrotic remodeling in affected tissues. This mechanism has potential applications in autoimmune and fibrotic diseases.
Approved indications
- Systemic sclerosis (scleroderma)
Common side effects
- Nausea
- Headache
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATB-1013 CI brief — competitive landscape report
- ATB-1013 updates RSS · CI watch RSS
- Autotelicbio portfolio CI